

**Samantha J. Zwiebel, MD**

Assistant Professor of Clinical Psychiatry,  
Department of Psychiatry,  
University of Pennsylvania, Philadelphia, PA

**Adele C. Viguera, MD**

Staff Psychiatrist, Department of Psychiatry,  
Neurological Institute, Cleveland Clinic,  
Cleveland, OH; Clinical Assistant Professor  
of Psychiatry, Cleveland Clinic Lerner  
College of Medicine of Case Western  
Reserve University, Cleveland, OH

# Discontinuing antidepressants: Pearls and pitfalls

## ABSTRACT

Stopping antidepressants can be challenging due to the high rate of discontinuation symptoms. Patients with antidepressant discontinuation syndrome (ADS) commonly experience insomnia, flu-like symptoms, mood disturbances, dizziness, and paresthesias, but a broad array of adverse effects is possible. Symptoms can last for days to months, and different symptoms have different durations. Patient education, identification of patients most at risk for developing symptoms, and a slow antidepressant taper or cross-taper are important steps in mitigating the risk of ADS and managing patient concerns about ADS. Tapers should be carried out over weeks to months. Discontinuation symptoms should be managed with restarting the prior dose of antidepressant and then tapering even more slowly, with additional symptomatic management as needed.

## KEY POINTS

Changing or stopping antidepressants, especially if done abruptly, can be associated with ADS.

Symptoms can present within hours and last for months due to the complex mechanisms of antidepressants.

Slow tapers should be carried out over weeks to months to minimize the risk of ADS.

Knowing risk factors for ADS can identify the most vulnerable patients.

**A**N EVER-INCREASING NUMBER OF PATIENTS are prescribed antidepressant medications, most often by primary care physicians,<sup>1</sup> with approximately 12.7% of the adult population in the United States prescribed a daily antidepressant.<sup>2</sup> Antidepressants are used to treat a variety of conditions other than mood and anxiety disorders, such as chronic pain syndromes, tobacco use disorder, and obsessive-compulsive disorder. Common scenarios prompting discontinuation of an antidepressant include the following:

- The condition for which the antidepressant was started is in remission for an appropriate maintenance period
- The antidepressant does not achieve a satisfactory effect<sup>3,4</sup>
- Intolerable side effects emerge
- New drug-drug interactions occur due to additional medication the patient must take
- The patient's prescription drug insurance coverage changes.

In the case of insurance coverage, clinicians are encouraged to advocate for the patient whenever a coverage issue arises in order to avoid changing antidepressants. Additionally, patients may choose to stop an antidepressant of their own accord.

Stopping antidepressants can be challenging because of the frequency of antidepressant discontinuation syndrome (ADS). Discontinuation symptoms occur commonly and vary in severity.<sup>5</sup> Symptoms will often surprise and frighten patients who are not forewarned, leading them to seek emergency medical care. Discontinuation symptoms include insomnia, flu-like symptoms, mood disturbances, dizziness, paresthesias ("brain zaps"), and a broad array of other adverse effects.<sup>6,7</sup>

doi:10.3949/ccjm.89a.21020

TABLE 1

**Clinical syndromes after discontinuing antidepressants**

Condition	Category	Onset, duration	Symptoms
Discontinuation syndrome	Acute withdrawal	Onset 36–96 hours Duration < 6 weeks	New symptoms not present before antidepressant was started or stopped
	Rebound	Onset 36–96 hours Duration < 6 weeks	Greater severity of original symptoms
	Persistent withdrawal syndrome	Onset 24 hours to 6 weeks Duration > 6 weeks	New symptoms and/or greater severity of original symptoms
New episode	Relapse	Onset < 6 weeks Duration variable	Original symptoms at original severity
	Recurrence	Onset > 6 months Duration variable	Original symptoms at original severity

Based on information in reference 9.

The range of risk factors for ADS indicates the complex mechanisms underlying discontinuation symptoms beyond acute medication cessation. But despite the frequent morbidity associated with stopping antidepressants, there is a notable lack of guidance for clinicians on tapering antidepressants or managing ADS,<sup>8</sup> and the majority of available guidelines are not considered evidence-based.<sup>5</sup> The following narrative review describes the array of discontinuation symptoms and their causes and provides practical clinical guidance for discontinuing antidepressants to minimize the risk of ADS. The principles discussed regarding medication discontinuation and switching to another antidepressant can be applied regardless of the antidepressant indication.

### ■ SYMPTOMS AND RISK OF ANTIDEPRESSANT DISCONTINUATION

ADS can pose diagnostic challenges because many symptoms of discontinuation overlap with those of toxicity and recurrence. ADS should be suspected if the patient reports either new symptoms that were not part of the original presentation or symptoms noted in the original presentation but at greater severity.<sup>9</sup>

ADS can be conceptualized into 3 categories: acute withdrawal (new symptoms for < 6 weeks), rebound (same symptoms with greater severity for < 6 weeks), and persistent withdrawal (new symptoms or same symptoms with greater severity for > 6 weeks). By contrast, new episodes of the original condition can occur after discontinuation, including relapse (same symptoms at the same severity emerge < 6 weeks) and recurrence (same symptoms at the same severity emerge > 6 months).<sup>9</sup> These definitions are summarized in **Table 1**.<sup>9</sup>

#### Risk of relapse

Patients who stop antidepressants, regardless of the specific psychiatric indication or duration of taper, are at a greater risk of relapse of psychiatric illness than those patients who remain on antidepressants.<sup>10</sup> A large meta-analysis<sup>10</sup> found the rate of 12-month relapse was 2.3 times higher in patients who had stopped antidepressants compared with those who continued treatment. Of patients who stopped antidepressants, 44.8% experienced a relapse or recurrence within 12 months compared with 19.5% of patients who continued antidepressants. The patients who stopped antidepressants also demonstrated a median time

**ADS can pose diagnostic challenges because symptoms of discontinuation may overlap with those of toxicity and recurrence**

to recurrence of about 14 months, compared with 48 months for patients who continued antidepressants.<sup>10</sup> Therefore, it is especially critical to distinguish between a recurrent episode and ADS.

Studies have shown that 27% to 86% of patients who attempt to stop antidepressants, whether on their own or under supervision of a physician, experience ADS.<sup>11</sup> One review<sup>11</sup> included studies ranging from randomized clinical trials to online surveys, with a weighted average of 56%. Of patients experiencing discontinuation symptoms, 86.7% reported ongoing symptoms at 2 months, 58.6% at 1 year, and 16.2% beyond 3 years.<sup>11</sup> Persistent discontinuation symptoms, often termed protracted withdrawal syndrome, is not formally defined but should be diagnosed when discontinuation symptoms persist beyond several months. Data from an Internet forum for patients<sup>12</sup> identified a mean duration of 37 months and a median duration of 26 months in persistent symptoms. Of forum users identified as having protracted withdrawal, 73.9% experienced various physical symptoms, 82.6% experienced affective symptoms, and 63.8% experienced both physical and affective symptoms. Sleep disturbances (43.5%) and cognitive symptoms (31.9%) were also very common.<sup>12</sup>

### Symptoms vary by drug class

Symptoms of ADS present across a range of organ systems and vary based on the antidepressant class and individual medication. **Table 2** summarizes the most typical symptoms, though symptoms can vary by individual medication since many medications, even within the same class, have different receptor profiles and affinities.<sup>6,7,13,14</sup> There is relatively little information available on tricyclics, tetracyclics, and monoamine oxidase inhibitors (MAOIs) relative to selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), in part because symptoms were often thought to be psychosomatic<sup>13</sup> and not of much importance at a time when tricyclics, tetracyclics, and MAOIs were more commonly used.<sup>9</sup>

There are also only limited data on atypical antidepressants such as mirtazapine and bupropion and newer medications such as vortioxetine and levomilnacipran.

### A useful diagnostic mnemonic

To simplify recognition of ADS, clinicians can use the mnemonic FINISH for flu-like symptoms, insomnia, nausea, imbalance (dizziness), sensory disturbances (parasthesias, including brain zaps), and hyperarousal (anxiety, irritability),<sup>15</sup> which are fairly generalizable across antidepressant classes.

### Suicidal ideation, panic, and other risks

Discontinuation of antidepressants can carry significant risk, including suicidal ideation, suicide, and mania. One study<sup>16</sup> of 73 patients investigating the role of adjunctive psychotherapy in antidepressant discontinuation had to be stopped due to ethical concerns stemming from lack of efficacy and a patient suicide. Another study<sup>17</sup> observed 28 patients undergoing antidepressant discontinuation and found suicidal ideation in 4 patients, all of whom were stopping paroxetine.

Panic and restlessness due to ADS likely exacerbate suicidal ideation, which in most cases is probably due to ADS rather than relapse.<sup>6</sup> Patients treated for panic disorder should be closely monitored for rebound.

Cessation of antidepressants can also elicit mania or hypomania. Although it is more frequent that patients experience depression following antidepressant discontinuation, the phenomenon of mania due to antidepressant cessation has been observed in at least 24 cases across various antidepressants.<sup>18</sup>

### Brain zaps: Unpleasant, sometimes disabling

Another notable discontinuation symptom is a type of paresthesia known colloquially as “brain zaps,” unpleasant and sometimes disabling electric shock-like sensations. These sensations may be due to adrenergic withdrawal. Therefore, SNRIs are expected to have a higher likelihood of causing brain zaps than SSRIs. Disproportionately higher rates of brain zaps are reported with venlafaxine but also with paroxetine, and they have been reported with many antidepressants.<sup>19</sup>

Electric shock-like sensations are most often seen in patients who have abruptly stopped antidepressant treatment or missed doses, though more than 30% of patients with brain zaps report these symptoms either while undergoing a taper or after completing a taper. Some patients may experience the zaps during normal treatment.

**To simplify recognition of ADS, use the mnemonic FINISH: flu-like symptoms, insomnia, nausea, imbalance, sensory disturbances, and hyperarousal**

TABLE 2

Discontinuation symptoms by antidepressant drug class

System	SSRIs	SNRIs	TCAs	MAOIs	Atypicals
General	Flu-like symptoms Fatigue	Flu-like symptoms Fatigue Diaphoresis	Flu-like symptoms Fatigue	Flu-like symptoms Fatigue	Flu-like symptoms Fatigue
Cardio-vascular	Tachycardia Flushing	Tachycardia Hypertension, hypotension Syncope	Tachycardia Arrhythmia	Tachycardia Arrhythmia	(Limited data)
Gastro-intestinal	Nausea, vomiting Diarrhea Anorexia	Nausea, vomiting Diarrhea Anorexia	Nausea, vomiting Diarrhea Anorexia	Nausea, vomiting Diarrhea Anorexia	Nausea, vomiting Diarrhea Anorexia (mirtazapine)
Neurologic	Headache Gait instability Dizziness Paresthesias, brain zaps Tremor, ataxia Myoclonus, muscle jerking Parkinsonism	Headache Gait instability Dizziness Parasthesias, brain zaps Tremor, ataxia Stroke-like symptoms Seizure, myoclonus, muscle jerking	Headache Paresthesias Tremor, ataxia Seizure Parkinsonism	Headache Paresthesias Tremor, ataxia Seizure, myoclonus, muscle jerking Parkinsonism Dystonia Catatonia	Headache Dizziness Paresthesias Tremor Dystonia (bupropion)
Psychiatric	Anxiety, panic Depression, mania Suicidal ideation Anger, irritability Mood swings Depersonalization, derealization Hallucinations	Anxiety, panic Depression, mania Suicidal ideation Anger, irritability Mood swings Depersonalization, derealization Hallucinations	Anxiety, panic Depression, mania Suicidal ideation Anger, irritability Mood swings Derealization Hallucinations Delusions	Depression, lability Suicidal ideation Anger, irritability Aggression, agitation Hallucinations Delusions	Anxiety, panic Depression, mania Suicidal ideation Anger, irritability Mood swings Depersonalization, derealization
Cognitive	Confusion, delirium Inattention	Confusion, delirium Inattention	Confusion, delirium Inattention	Confusion, delirium Inattention	(Limited data)
Sleep	Sleep disturbances Nightmares, vivid dreams	Sleep disturbances Nightmares, vivid dreams	Sleep disturbances Nightmares, vivid dreams	Sleep disturbances Nightmares, vivid dreams	Sleep disturbances Nightmares, vivid dreams
Visual	Vision changes	Vision changes	Vision changes	Vision changes	(Limited data)
Sexual	Dysfunction	Dysfunction	Dysfunction	Dysfunction	Dysfunction

MAOIs = monoamine oxidase inhibitors; SNRIs = serotonin-norepinephrine reuptake inhibitors; SSRIs = selective serotonin reuptake inhibitors; TCAs = tricyclic and tetracyclic antidepressants

Based on information in references 6,7,13,14.

The sensations typically last a few weeks but can persist for years and may be associated with dizziness, the perception of crackling or sizzling noises, and various other symptoms such as depersonalization (feeling detached from and outside of one's own body) and derealization (the sensation that the external world is unreal). Common triggers are eye and head movements, but patients note many other triggering activities. There are no known treatments that successfully and specifically target brain zaps other than resuming the medication at the previous dose.<sup>19</sup>

### DISCONTINUATION SYNDROME VS WITHDRAWAL

There is controversy surrounding the terminology of ADS vs antidepressant withdrawal. While clinically the terms are often used interchangeably, it is important to appreciate the nuanced meaning of each term.

Withdrawal from antidepressants may imply addiction.<sup>3,20</sup> However, patients do not crave antidepressants, experience intoxication, or exhibit other hallmarks of a substance use disorder, such as using more and more drug despite negative consequences.<sup>17</sup> Therefore, clinically, the term discontinuation is preferred over withdrawal. Some other authors argue that the term discontinuation downplays the severity of the emergent symptoms, which can be intensely uncomfortable and impairing.<sup>21</sup> These authors strongly favor the use of antidepressant withdrawal because the syndrome of antidepressant discontinuation is consistent with withdrawal from other substances,<sup>6,7,21,22</sup> and because antidepressants cause dependence.<sup>12</sup>

ADS has been clinically recognized for decades,<sup>13,23–25</sup> demonstrating emergence of symptoms within days or even hours of abrupt cessation. Clinical trials that transitioned patients on antidepressants to placebo observed discontinuation symptoms, especially in antidepressants with shorter half-lives.<sup>23,24</sup> However, many patients experiencing such symptoms are misdiagnosed as experiencing a relapse or a psychosomatic reaction.<sup>13,25</sup> With growing recognition of the difficulty in stopping antidepressants, the risk of ADS should be discussed with patients as part of an informed-consent process when starting antidepressants.<sup>25</sup>

### THE PHARMACOKINETICS BEHIND DISCONTINUATION SYNDROME

Straightforward pharmacokinetic explanations of discontinuation symptoms are inadequate since symptoms continue to emerge over a period of weeks and can last for months and even years.<sup>22</sup> Antidepressants are believed to exert their effect partly through chronic medication exposure leading to receptor downregulation to create a more favorable neurotransmitter-to-receptor ratio.<sup>6,7,26–28</sup> It should be noted that each class of antidepressants exerts its effect in different ways; therefore, broad statements about antidepressant mechanisms of action tend to be overgeneralizations. Still, the mechanism of receptor downregulation, which requires weeks to months and may over time contribute to medication desensitization, likely accounts in part for prolonged discontinuation symptoms.<sup>12</sup>

Furthermore, it is also hypothesized that antidepressants with anticholinergic properties may lead to receptor upregulation rather than downregulation and thus can contribute to desensitization.<sup>13</sup> The theory of “oppositional tolerance” incorporates both upregulation and downregulation,<sup>22</sup> because discontinuing antidepressants may lead to diverse rebound symptoms due to the widespread distribution of serotonin throughout the body. Oppositional tolerance that develops and increases over time may explain why patients treated with antidepressants at higher doses and for longer periods are at greater risk for ADS.<sup>29</sup>

### WHO IS MOST AT RISK OF DISCONTINUATION SYMPTOMS?

Despite extensive literature on ADS, there is still little known about the patient characteristics that pose the most risk.<sup>7,14</sup> Nevertheless, though the risk of ADS cannot be eliminated, it can be reduced through awareness of known risk factors (**Table 3**).<sup>6,7,14,23,24,26,28–32</sup>

Some patients may have a genetic predisposition,<sup>7</sup> although this is yet to be determined. Younger patients may be more at risk, but younger patients are also more likely to abruptly discontinue their antidepressants.<sup>30</sup> Patients who report discontinuation symptoms during missed doses are also at higher risk of withdrawal during a taper,<sup>28</sup> and pa-

**There are no known treatments for brain zaps other than resuming the medication at the previous dose**

tients should be asked about this experience during an appointment to plan a taper.<sup>31</sup>

Treatment of longer duration<sup>6,26,29</sup> and at treatment at higher doses<sup>29</sup> have proven to be risk factors for ADS. Medications with higher receptor affinity such as paroxetine carry greater risk.<sup>26</sup> Abrupt discontinuation of antidepressants increases the risk of ADS.<sup>32</sup> The indication for the prescribed antidepressant does not appear to affect the likelihood of ADS symptoms.<sup>6</sup>

Medication half-life inversely predicts the risk of discontinuation.<sup>6,23,24</sup> Of the SSRIs, paroxetine and fluvoxamine have the shortest half-lives and therefore are associated with the highest risk. Citalopram, escitalopram, and sertraline carry moderate risk, while fluoxetine carries the lowest risk due to the long half-life of its active metabolite (approximately 7 days).<sup>7</sup> Among SNRIs, venlafaxine and desvenlafaxine carry the highest risk for ADS. Duloxetine carries a high risk and milnacipran a low risk, with levomilnacipran carrying the lowest risk.<sup>14</sup> MAOIs and tricyclic and tetracyclic antidepressants generally carry a relatively high risk for ADS. Although mirtazapine and bupropion carry some risk, the data on this are limited.<sup>6</sup>

To date, there are only minimal prospective data comparing the risk of ADS with different antidepressants. A recent review<sup>9</sup> concluded that paroxetine and venlafaxine pose the greatest risk among antidepressants most commonly prescribed today. **Table 4** stratifies antidepressants by the risk of ADS.

**■ PREVENTING AND MANAGING DISCONTINUATION SYMPTOMS**

To date, no formal schedules for tapering antidepressants have been validated. The maxim “slower is better” applies to tapering antidepressants. Most authors now agree that a longer taper, defined as at least 14 days, may reduce the risk of discontinuation symptoms compared with a rapid taper, defined as 1 to 10 days.<sup>17</sup> Current recommendations advise antidepressant dose adjustments every 1 to 4 weeks.<sup>26</sup> Data from the field of sleep medicine, where patients are often instructed to hold antidepressants, suggest tapers over 3 to 4 months.<sup>33</sup> Some have suggested the “10% rule,” which recommends reducing the dose

**TABLE 3**

**Risk factors for antidepressant discontinuation syndrome**

- Longer duration of treatment
- Higher dose of drug
- Shorter half-life of drug
- Higher receptor affinity of drug
- Younger patient age
- History of discontinuation symptoms
- Abrupt discontinuation
- High-risk medication (see Table 4)

Based on information in references 6,7,14,23,24,26,28–32.

by 10% weekly.<sup>26</sup> Switching to a liquid formulation can facilitate slow tapers by enabling precise dosing. However, neither paroxetine nor venlafaxine, common antidepressants very likely to cause ADS, is readily available in liquid formulation. Patients report opening capsules to divide up beads, as well as breaking unscored tablets with pill cutters to slowly taper off medication.<sup>11,28</sup> Patients can also utilize compounding pharmacies to access custom formulations.

**■ TAPERING TO CHANGE ANTIDEPRESSANT MEDICATIONS**

When switching from one antidepressant to another, taper considerations are different. Cross-tapering is generally recommended<sup>4</sup> and can be carried out over 1 to 4 weeks or longer depending on the dosing of the original medication. Cross-tapering involves incrementally decreasing the current antidepressant while incrementally increasing the new antidepressant (**Table 4**).

Other ways to change antidepressants include starting the new antidepressant immediately after stopping the previous drug (direct switch), starting the new drug after 2 to 3 days off the prior drug (moderate switch), and starting the new drug after 5 half-lives off the prior drug (conservative switch). A direct switch can be considered when changing an SSRI to another SSRI or SNRI at an equivalent dose, unless the current SSRI is at a high

**To date, there are only minimal prospective data comparing the risk of ADS with different antidepressants**

**TABLE 4**

**Risk of antidepressant discontinuation syndrome (ADS):  
A summary of antidepressant dosing**

Risk of ADS	Name (brand name)	Starting daily dose (mg)	Daily dose range (mg)	Typical dose increment (mg) (conservative dose increment)
Low	Bupropion XL (Wellbutrin XL) <sup>a</sup>	150	150–450	150
	Doxepin (Silenor)	3	3–6	3
	Fluoxetine (Prozac) <sup>a</sup>	10	10–80	10
	Levomilnacipran (Savella)	20	20–120	40 (20)
	Milnacipran (Fetzima)	25	50–300	25–50 (12.5)
	Vilazodone (Viibryd)	10	10–40	10
	Citalopram (Celexa)	10	10–40	10
	Escitalopram (Lexapro)	5	5–30	10 (5)
	Mirtazapine (Remeron)	7.5–15	7.5–60	15 (7.5)
Intermediate	Sertraline (Zoloft)	25	25–300	50 (12.5–25)
	Trazodone (Deseryl)	25–50	25–400	50 (25)
	Vortioxetine (Trintellix)	5	5–20	5
	Amitriptyline (Elavil)	10–25	10–300	50 (10–25)
	Clomipramine (Anafranil)	25	25–300	50 (25)
	Desipramine (Norpramin)	25	25–300	25–50 (10–25)
	Desvenlafaxine (Pristiq)	25	50–400	50 (25)
	Doxepin (Sinequan)	25	25–300	25–50 (10–25)
	Duloxetine DR (Cymbalta DR)	20–30	30–120	30 (20)
High	Fluvoxamine (Luvox) <sup>b</sup>	25	25–300	50 (12.5–25)
	Imipramine (Tofranil)	25	25–300	25–50 (10–25)
	Nortriptyline (Pamelor)	10–50	10–150	25–50 (10–25)
	Paroxetine (Paxil) <sup>a</sup>	10	10–50	10 (5)
	Phenelzine (Nardil)	15	7.5–90	15
	Tranlycypromine (Parnate)	10	10–60	10
	Venlafaxine ER (Effexor ER)	37.5	75–375	37.5

<sup>a</sup>Potent CYP 2D6 inhibitor.

<sup>b</sup>Potent CYP 1A2 inhibitor.

dose. Moderate and conservative switches carry the risk of ADS due to the time spent completely off an antidepressant.<sup>4</sup> Alternatively, cross-tapering carries the risk of causing drug-drug interactions, and clinicians should be aware of potential risks such as serotonin syndrome. None of these switching methods

are appropriate for MAOIs, which require a 14-day washout both pre- and post-treatment, and at least a 5-week washout if MAOI treatment is preceded by fluoxetine.<sup>34</sup>

Studies have suggested discontinuing antidepressants by switching patients to fluoxetine due to its 7-day half-life and rela-

tively low risk of ADS.<sup>23,35</sup> There are no formal guidelines on fluoxetine-assisted tapers, but the strategy consists of cross-tapering to fluoxetine (slowly decreasing the original antidepressant while increasing fluoxetine to a dosing required for ADS remission) followed by discontinuation of fluoxetine,<sup>26</sup> which can self-taper due to its long half-life. Such a strategy can be helpful when tapering off venlafaxine, desvenlafaxine, paroxetine, and tricyclic and tetracyclic antidepressants. However, clinicians must be wary of drug-drug interactions due to fluoxetine's CYP 2D6 inhibition, which can raise drug levels.

Additional practical guidance on discontinuing and switching antidepressants can be found online.<sup>36,37</sup>

### Patient education and other management tools

Perhaps the most pragmatic and effective measure in managing ADS is to proactively educate patients about FINISH symptoms with missed doses or abrupt discontinuation. This prepares patients to better cope with ADS during planned antidepressant discontinuation and may prevent unnecessary visits to the emergency room. It is also important to reassure the patient that ADS is neither life-threatening nor indicative of addiction, and that it will eventually resolve.

If ADS does occur, the antidepressant being tapered can be rapidly resumed at the previous dosing and then tapered more slowly. This intervention is the simplest antidote and is highly effective in most cases within 24 hours.

Symptom management is another treatment strategy.<sup>35</sup> For example, headaches can be managed with ibuprofen 400 mg or acetaminophen 650 mg every 4 to 6 hours. Nausea can be addressed with ondansetron 4 mg every 8 hours. Anxiety and insomnia can be managed with hydroxyzine 50 mg every 6 hours or with benzodiazepines. In some cases, diphenhydramine can be recommended if the patient is stopping a particularly anticholinergic antidepressant, such as paroxetine.

Additionally, antidepressants can have extensive drug-drug interactions. These interactions can occur from enzymatic induction or inhibition of the cytochrome P450

system or from medication side effects that overlap with the effect of other medications, such as additive effects in anticoagulation. The cessation of an antidepressant therefore requires the reevaluation of other concurrently prescribed medications.<sup>22</sup> While it is always recommended to complete a medication review, changes in bupropion, fluoxetine, and paroxetine (potent CYP 2D6 inhibitors), fluvoxamine (a potent CYP 1A2 inhibitor), tricyclic and tetracyclic antidepressants, and MAOIs should prompt an especially close medication review.

### FUTURE DIRECTIONS

Translational efforts including the further development of animal models for ADS are needed to enhance our understanding of the pathogenesis, phenotypic variance, and role of genetic and environmental modulation in ADS. Such efforts will help the clinician screen for a medication's potential to induce ADS and will contribute to developing agents that reduce the symptoms and severity of ADS.<sup>38</sup>

### TAKE-HOME POINTS

- Discontinuing or changing antidepressants, especially when done quickly, can be associated with ADS, and symptoms can emerge within hours and last for months.
- The mnemonic FINISH is useful for recognizing ADS: flu-like symptoms, insomnia, nausea, imbalance, sensory disturbances (eg, brain zaps), and hyperarousal.
- Dosing adjustments should be made every 1 to 4 weeks and may require months to complete. Patients unable to tolerate a tapering schedule should be tapered more slowly with supplemental symptomatic management.
- Risk factors for ADS are higher dose and longer duration of treatment, medication with shorter half-life and greater receptor affinity, abrupt discontinuation, prior symptoms with missed doses or previous antidepressant discontinuations, and younger patient age. ■

### DISCLOSURES

The authors report no relevant financial relationships which, in the context of their contributions, could be perceived as a potential conflict of interest.

**It is important to reassure the patient that ADS is neither life-threatening nor indicative of addiction, and that it will eventually resolve**



## REFERENCES

- Davidson JR. Major depressive disorder treatment guidelines in America and Europe. *J Clin Psychiatry* 2010; 71(suppl E1):e04. doi:10.4088/JCP.9058se1c.04gry
- Van Leeuwen E, van Driel ML, Horowitz MA, et al. Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults. *Cochrane Database Syst Rev* 2021; 4(4):CD013495. doi:10.1002/14651858.CD013495.pub2
- Keks N, Hope J, Keogh S. Switching and stopping antidepressants. *Aust Prescr* 2016; 39(3):76–83. doi:10.18773/austprescr.2016.039
- Jefferson JW. Strategies for switching antidepressants to achieve maximum efficacy adolescents. *J Clin Psychiatry* 2008; 69(suppl E1):14–18. PMID:18494539
- Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guidelines evidence-based? *Addict Behav* 2019; 97:111–121. doi:10.1016/j.addbeh.2018.08.027
- Hensler J, Heinz A, Brandt L, Bschor T. Antidepressant withdrawal and rebound phenomena. *Dtsch Arztebl Int* 2019; 116(20):355–361. doi:10.3238/arztebl.2019.0355
- Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. *Psychother Psychosom* 2015; 84(2):72–81. doi:10.1159/000370338
- Wilson E, Lader M. A review of the management of antidepressant discontinuation symptoms. *Ther Adv Psychopharmacol* 2015; 5(6):357–368. doi:10.1177/2045125315612334
- Cosci F, Chouinard G. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. *Psychother Psychosom* 2020; 89(5):283–306. doi:10.1159/000506868
- Viguera AC, Baldessarini RJ, Friedberg J. Discontinuing antidepressant treatment in major depression. *Harv Rev Psychiatry* 1998; 5(6):293–306. doi:10.3109/10673229809003578
- All-Party Parliamentary Group for Prescribed Drug Dependence. Antidepressant withdrawal: a survey of patients' experience by the All-Party Parliamentary Group for Prescribed Drug Dependence. <http://prescribeddrug.org/wp-content/uploads/2018/09/APPG-PDD-Antidepressant-Withdrawal-Patient-Survey.pdf>. Accessed December 15, 2021.
- Hengartner MP, Schulthess L, Sorensen A, Framer A. Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum. *Ther Adv Psychopharmacol* 2020. Published December 24, 2020. doi:10.1177/2045125320980573
- Garner EM, Kelly MW, Thompson DF. Tricyclic antidepressant withdrawal syndrome. *Ann Pharmacother* 1993; 27(9):1068–1072. doi:10.1177/106002809302700912
- Fava GA, Benasi G, Lucente M, Offidani E, Cosci F, Guidi J. Withdrawal symptoms after serotonin-noradrenaline reuptake inhibitor discontinuation: systematic review. *Psychother Psychosom* 2018; 87(4):195–203. doi:10.1159/000491524
- Berber MJ. FINISH: remembering the discontinuation syndrome. Flu-like symptoms, insomnia, nausea, imbalance, sensory disturbances, and hyperarousal (anxiety/agitation). *J Clin Psychiatry* 1998; 59(5):255. PMID:9632038
- Scholten WD, Batelaan NM, van Oppen P, et al. The efficacy of a group CBT relapse prevention program for remitted anxiety disorder patients who discontinue antidepressant medication: a randomized controlled trial. *Psychother Psychosom* 2018; 87(4):240–242. doi:10.1159/000489498
- Tint A, Haddad PM, Anderson IM. The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study. *J Psychopharmacol* 2008; 22(3):330–332. doi:10.1177/0269881107081550
- Narayan V, Haddad PM. Antidepressant discontinuation manic states: a critical review of the literature and suggested diagnostic criteria. *J Psychopharmacol* 2011; 25(3):306–313. doi:10.1177/0269881109359094
- Papp A, Onton JA. Brain zaps: an underappreciated symptom of antidepressant discontinuation. *Prim Care Companion CNS Disord* 2018; 20(6):18m02311. doi:10.4088/PCC.18m02311
- National Collaborating Centre for Mental Health (UK). Depression: the treatment and management of depression in adults (updated edition). Leicester, UK: British Psychological Society; 2010.
- Massabki I, Abi-Jaoude E. Selective serotonin reuptake inhibitor 'discontinuation syndrome' or withdrawal. *Br J Psychiatry* 2021; 218(3):168–171. doi:10.1192/bjp.2019.269
- Fava GA, Cosci F. Understanding and managing withdrawal syndromes after discontinuation of antidepressant drugs. *J Clin Psychiatry* 2019; 80(6):19com12794. doi:10.4088/JCP.19com12794
- Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. *Biol Psychiatry* 1998; 44(2):77–87. doi:10.1016/s0006-3223(98)00126-7
- Michelson D, Fava M, Amsterdam J, et al. Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. *Br J Psychiatry* 2000; 176:363–368. doi:10.1192/bjp.176.4.363
- Guy A, Brown M, Lewis S, Horowitz M. The 'patient voice': patients who experience antidepressant withdrawal symptoms are often dismissed, or misdiagnosed with relapse, or a new medical condition. *Ther Adv Psychopharmacol* 2020. Published November 9, 2020. doi:10.1177/2045125320967183
- Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. *Lancet Psychiatry* 2019; 6(6):538–546. doi:10.1016/S2215-0366(19)30032-X
- Schatzberg AF, Haddad P, Kaplan EM, et al. Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome. Discontinuation Consensus Panel. *J Clin Psychiatry* 1997; 58(suppl 7):23–27. PMID:9219490
- Jha MK, Rush AJ, Trivedi MH. When discontinuing SSRI antidepressants is a challenge: management tips. *Am J Psychiatry* 2018; 175(12):1176–1184. doi:10.1176/appi.ajp.2018.18060692
- University of Oxford. Report of the CSM expert working group on the safety of selective serotonin reuptake inhibitor antidepressants. <https://study329.org/wp-content/uploads/2015/01/CSMReportonSSRISafety1.pdf>. Accessed December 15, 2021.
- Himeji A, Okamura T. Discontinuation syndrome associated with paroxetine in depressed patients: a retrospective analysis of factors involved in the occurrence of the syndrome. *CNS Drugs* 2006; 20(8):665–672. doi:10.2165/00023210-200620080-00005
- Shelton RC. Steps following attainment of remission: discontinuation of antidepressant therapy. *Prim Care Companion J Clin Psychiatry* 2001; 3(4):168–174. doi:10.4088/pcc.v03n0404
- van Geffen EC, Hugtenburg JG, Heerdink ER, van Hulten RP, Egberts AC. Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation. *Eur J Clin Pharmacol* 2005; 61(4):303–307. doi:10.1007/s00228-005-0921-x
- Phelps J. Tapering antidepressants: is 3 months slow enough? *Med Hypotheses* 2011; 77(6):1006–1008. doi:10.1016/j.mehy.2011.08.035
- Aboukarr A, Giudice M. Interaction between monoamine oxidase B inhibitors and selective serotonin reuptake inhibitors. *Can J Hosp Pharm* 2018; 71(3):196–207. PMID:29955193
- Schatzberg AF, Blier P, Delgado PL, Fava M, Haddad PM, Shelton RC. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. *J Clin Psychiatry* 2006; 67(suppl 4):27–30. PMID:16683860
- Hirsch M, Birnbaum RJ. Discontinuing antidepressant medications in adults. <https://www.uptodate.com/contents/discontinuing-antidepressant-medications-in-adults>. Accessed December 13, 2021.
- Hirsch M, Birnbaum RJ. Switching antidepressant medications in adults. <https://www.uptodate.com/contents/switching-antidepressant-medications-in-adults>. Accessed December 13, 2021.
- Zabegalov KN, Kolesnikova TO, Khatsko SL, et al. Understanding antidepressant discontinuation syndrome (ADS) through preclinical experimental models. *Eur J Pharmacol* 2018; 829:129–140. doi:10.1016/j.ejphar.2018.04.003

Address: Samantha J. Zwiebel, MD, Assistant Professor of Clinical Psychiatry, Department of Psychiatry, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104; [zwiebel@penmedicine.upenn.edu](mailto:zwiebel@penmedicine.upenn.edu)